Developing a new HIV vaccine using nanoparticles and engineered mRNA
Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery
This study is working on a new HIV vaccine that uses tiny particles to boost the immune system's response, aiming to give people better protection against HIV infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10979148 on NIH RePORTER |
What this research studies
This research focuses on creating a more effective vaccine for HIV by integrating nanoparticles derived from adjuvants with engineered mRNA. The approach aims to enhance the immune response by stimulating specific receptors in the immune system, which can lead to better protection against HIV. By using advanced techniques to improve the delivery of vaccine components and the design of immunogens, the research seeks to overcome existing challenges in HIV vaccine development. Patients may benefit from a more effective vaccine that could provide better protection against HIV infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for HIV infection or those who are currently living with HIV.
Not a fit: Patients who are not at risk for HIV or who have already been effectively treated and are not seeking vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a highly effective HIV vaccine, significantly reducing the incidence of HIV infections.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance vaccine efficacy, indicating potential for success in this novel application.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Dong, Yizhou — Icahn School of Medicine at Mount Sinai
- Study coordinator: Dong, Yizhou
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.